Solid Biosciences (Solid Biosciences) Operating Cash Flow per Share : $-3.98 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Operating Cash Flow per Share?

Solid Biosciences's operating cash flow per share for the three months ended in Mar. 2024 was $-0.66. Solid Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.98.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 33.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 31.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Solid Biosciences's Operating Cash Flow per Share or its related term are showing as below:

SLDB' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -112.9 Med: 18.3 Max: 33.8
Current: 33.8

During the past 9 years, Solid Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 33.80% per year. The lowest was -112.90% per year. And the median was 18.30% per year.

SLDB's 3-Year OCF Growth Rate is ranked better than
82.83% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs SLDB: 33.80

Solid Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Solid Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Operating Cash Flow per Share Chart

Solid Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-34.52

-16.35

-10.93

-11.51

-4.74

Solid Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-1.43	-1.40	-0.89	-1.03	-0.66

Competitive Comparison of Solid Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Solid Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Price-to-Operating-Cash-Flow falls into.

Solid Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Solid Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-94.18	/	19.884
	=	-4.74

Solid Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-25.192	/	38.155
	=	-0.66

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.98

Solid Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Solid Biosciences (Solid Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129

Website

https://www.solidbio.com

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Kevin Tan	officer: CFO & Treasurer	20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot	director, officer: Chief Executive Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
David T Howton	officer: See Remarks	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jennifer Marlowe	officer: CSO, FA & Cardiac	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Paul Herzich	officer: Chief Technology Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan	officer: Chief Regulatory Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Gabriel Brooks	officer: Chief Medical Officer	C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris	officer: Chief Scientific Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Clare Kahn	director	141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Bcls Sb Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116